Novacyt de volgende biotech raket!

32.251 Posts, Pagina: « 1 2 3 4 5 6 7 8 ... 1609 1610 1611 1612 1613 » | Laatste
boer_staf
0
Ik ben hier iets te vroeg ingestapt op 0,85 maar geloof ook nog steeds in een koers boven de 1 euro dit jaar. Sterke groei gaat zich doorzetten!
SJURVM
0
And the reaction is there to see +13.51% so far

I think it is the beginning of the turn for novacyt.

Maybe another conversion of those convertible bonds to raise cash by year-end but from 2018 cash flow should be positive.

and also profit making...
One to leave alone for a number of years I think
SJURVM
0
Invest Securities re-affirms a €1.8 target for the company with apparently some news about the listing on the AIM shortly.

They reckon Novacyt will need another €3m of fresh cash before being self financing in 2018.

[verwijderd]
0
boer_staf
0
Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces the appointment of Paul Eros as Commercial Director of Primerdesign, effective from 1 November 2017.

Paul has over thirty years’ of experience within the field of molecular diagnostics, including strategic global marketing, sales and product management. He joins Novacyt from DiaSorin, where he was Vice President of Molecular Marketing for over five years. Paul started his career with Becton Dickinson, quickly progressing through the sales and marketing organisation in both the UK and France, before joining Roche Diagnostics in 1999, where he held a number of senior international commercial and operational roles.

Paul’s appointment completes Novacyt’s investment in its senior commercial leadership team, building on the earlier Group appointments of Ruth Powell and Phil Sefton. Ruth Powell was appointed as Managing Director of the NovaPrep® division and Phil Sefton as Managing Director of Lab21 Products division.

Momentum within the Primerdesign business continues to build, driven by the strength of the commercial pipeline and increasing breadth of the molecular product offering. In addition, Primerdesign has increased its focus on building its business-to-business (“B2B”) pipeline which is developing well. Management expect this new vertical to form a significant part of future revenues and its first three B2B design prototyping and development contracts have recently been secured for delivery in Q4 2017.

Graham Mullis, Group CEO of Novacyt, commented:

“We are delighted to welcome Paul to the Company at this important juncture in our growth. We have made significant progress growing our business-to-business channel in Primerdesign and have already signed three new design prototyping and development contracts for Q4 2017. Paul’s considerable blue-chip commercial expertise specifically in molecular diagnostics will be hugely beneficial as we aim to convert our healthy pipeline of clinical projects and B2B opportunities into new contracts. We remain committed to investing in commercial expansion and I have been pleased with the important and early positive impact that Ruth and Phil have already made to the Group. I am confident that we have invested in a strong senior leadership team that can continue to drive growth from the many opportunities that we see.”
SJURVM
0
SJURVM
0
Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces that it has raised a total of €9.7 million (before expenses) through a conditional placing (the "Placing”) of 7,051,590 new shares (the "Placing Shares”), raising €4.7 million, and through an unconditional direct subscription (the "Subscription”) of 7,687,989 new shares (the "Subscription Shares”), raising €5.0 million, both at an issue price of 59.38 pence (€0.66) per share (the "Issue Price”) with support from new UK institutional investors and both new and current French institutional investors.
SJURVM
0
In addition, the Company announces the publication of its AIM admission document and its intention to obtain a dual-listing by applying for the admission of the Company’s issued and to be issued shares (the "Enlarged Share Capital”) to trading on AIM, a market operated by the London Stock Exchange ("AIM Admission”).

The first tranche of Subscription Shares, representing gross funds raised of €5.0 million, has been unconditionally issued and admission of these shares is expected to become effective on Euronext Growth Paris on 19 October 2017, unconditional on AIM Admission. The balance of Subscription Shares and all Placing Shares, representing gross funds raised of €4.7 million, are expected to be issued on 1 November 2017, with AIM Admission becoming effective and dealings in the Enlarged Share Capital commencing on AIM on 1 November 2017.
wieweet
0
Dus nu instappen...? Kijk even morgen vroeg of de koers nog iets gaat dalen anders vol erin...hmmmm of maar een beetje?


vrgr
boer_staf
0
Ik denk dat nu een heel erg mooi instappunt is. Zelf ga ik niet meer bijkopen, heb al voldoende erin zitten. Al maak ik me weinig zorgen dat ik vlug uit het rood zal komen. Binnen een jaar gaan we lachen om deze prijzen :)
SJURVM
0
quote:

wieweet schreef op 18 oktober 2017 21:58:


Dus nu instappen...? Kijk even morgen vroeg of de koers nog iets gaat dalen anders vol erin...hmmmm of maar een beetje?


vrgr


If you have not yet and with such deep discount you could definitely go for it.

The company is now assured of its funding for quite awhile.
With the second listing it will attract more interest with additional UK investors who will no longe have the potential currency risk

It might take a few months of course or at least until financial figures come out.
We shall see ...
[verwijderd]
0
Morgen eerste handelsdag in Londen.
Ben benieuwd hoeveel volume dat geeft.
Hopelijk kan het wat positief sentiment brengen.

Al met al ben ik positief over deze operatie.
Ondanks dat de uitgifte-prijs erg tegenviel.
Het opgehaalde bedrag viel me erg mee, en gezien de volumes en koersverloop is bijna alles in vaste handen terecht gekomen.

Geen idee wat er morgen gaat gebeuren, maar het kan bijna niet anders dat het een keer flink gaat bouncen.
wieweet
0
Gebeurd weinig tot niks met dit aandeel. Even tot vrijdag aankijken anders gaan ze verlopig even uit.


vrgr
32.251 Posts, Pagina: « 1 2 3 4 5 6 7 8 ... 1609 1610 1611 1612 1613 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 22 okt 2020 17:35
Koers 12,120
Verschil +1,260 (+11,60%)
Hoog 12,580
Laag 10,700
Volume 6.886.162
Volume gemiddeld 2.639.691
Volume gisteren 3.322.189